Therapix Biosciences

Tel Aviv Stock Exchange: TRPX

Market Cap$1.7m

Last Close $0.49

Therapix Biosciences is an Israeli pharmaceutical company developing two cannabinoids to treat Tourette syndrome and mild cognitive impairment. It is currently in Phase IIa and soon to begin Phase I, respectively, and owns or licenses several IPs for cannabinoid nasal and sublingual administration.

More Therapix Biosciences content >

Investment summary

Therapix is investigating the potential of new formulations of cannabinoids to address under-served diseases of the brain. It recently announced the results of its Phase IIa study of THX-110 for the treatment of Tourette’s syndrome. The study showed a statistically significant (p=0.002) reduction in tic severity of 21%. The company also recently announced data for THX-110 in obstructive sleep apnea. Of the nine patients who completed the study, five exhibited significant improvements in the primary endpoint of change in the Apnea–Hypopnea Index.

Y/E Dec
Revenue (US$m)
PBT (US$m)
EPS (c)
P/E (x)
P/CF (x)
2015A N/A N/A N/A N/A N/A N/A
2016A 0.0 (1.7) (1.7) (179.9) N/A N/A
2017E 0.0 (4.0) (4.3) (118.4) N/A N/A
2018E 0.0 (7.7) (7.7) (200.1) N/A N/A
Industry outlook

Diseases of the brain are a major unmet medical need, with few effective or approved therapies for a host of diseases. Cannabinoids have had promising data in many indications in the area and is a class that has received a lot of interest.

Last updated on 03/02/2020
Content on Therapix Biosciences
Termination of coverage – Therapix Biosciences
Healthcare | Termination | 12 February 2020
Therapix Biosciences – THX-ULD01 to focus on TBI
Healthcare | Update | 14 August 2018
View more
Share price graph
Balance sheet
Forecast net cash (US$m) 9.8
Forecast gearing ratio (%) N/A
Price performance
Actual (53.3) (80.1) (87.3)
Relative* (53.5) (81.2) (89.4)
52-week high/low US$4.7/US$0.5
*% relative to local index
Key management
Elran Haber CEO
Josh Blacher CFO Designate